Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 69

Similar articles for PubMed (Select 17546575)

1.

Interpreting clinically significant changes in patient-reported outcomes.

Ringash J, O'Sullivan B, Bezjak A, Redelmeier DA.

Cancer. 2007 Jul 1;110(1):196-202.

2.

Interpreting differences in quality of life: the FACT-H&N in laryngeal cancer patients.

Ringash J, Bezjak A, O'Sullivan B, Redelmeier DA.

Qual Life Res. 2004 May;13(4):725-33.

PMID:
15129883
3.

Quality of life and utility in irradiated laryngeal cancer patients.

Ringash J, Redelmeier DA, O'Sullivan B, Bezjak A.

Int J Radiat Oncol Biol Phys. 2000 Jul 1;47(4):875-81.

PMID:
10863055
4.

Clinical significance of health status assessment measures in head and neck cancer: what do quality-of-life scores mean?

Funk GF, Karnell LH, Smith RB, Christensen AJ.

Arch Otolaryngol Head Neck Surg. 2004 Jul;130(7):825-9.

PMID:
15262758
5.

Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis.

Siddiqui F, Pajak TF, Watkins-Bruner D, Konski AA, Coyne JC, Gwede CK, Garden AS, Spencer SA, Jones C, Movsas B.

Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):353-60. Epub 2007 Sep 24.

PMID:
17889449
6.

Health-related quality of life measures in routine clinical care: can FACT-fatigue help to assess the management of fatigue in cancer patients?

Santana MJ, Au HJ, Dharma-Wardene M, Hewitt JD, Dupere D, Hanson J, Ghosh S, Feeny D.

Int J Technol Assess Health Care. 2009 Jan;25(1):90-6. doi: 10.1017/S0266462309090126.

PMID:
19126256
7.

Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.

Cella D, Li JZ, Cappelleri JC, Bushmakin A, Charbonneau C, Kim ST, Chen I, Motzer RJ.

J Clin Oncol. 2008 Aug 1;26(22):3763-9. doi: 10.1200/JCO.2007.13.5145.

8.

Quality-of-life outcomes in head and neck cancer patients.

Morton RP, Izzard ME.

World J Surg. 2003 Jul;27(7):884-9. Review.

PMID:
14509523
9.

Hyperfractionated, accelerated radiotherapy for locally advanced head and neck cancer: quality of life in a prospective phase I/II trial.

Ringash J, Lockwood G, O'Sullivan B, Warde P, Bayley A, Cummings B, Kim J, Sellmann S, Waldron J.

Radiother Oncol. 2008 May;87(2):181-7. doi: 10.1016/j.radonc.2007.12.028. Epub 2008 Jan 22.

PMID:
18215435
10.

Estimation of patient preference-based utility weights from the functional assessment of cancer therapy - general.

Dobrez D, Cella D, Pickard AS, Lai JS, Nickolov A.

Value Health. 2007 Jul-Aug;10(4):266-72.

PMID:
17645681
11.

[Quality of life of patients with malignant tumors of the head and neck area with special reference to laryngectomy patients].

Houser A, Kramp B, Richter J, Dässler U.

Laryngorhinootologie. 2001 Aug;80(8):458-63. German.

PMID:
11552425
12.

Quality of life and voice in patients treated for early laryngeal cancer.

Siupsinskiene N, Vaitkus S, Grebliauskaite M, Engelmanaite L, Sumskiene J.

Medicina (Kaunas). 2008;44(4):288-95.

13.

Free-flap head and neck reconstruction and quality of life: a 2-year prospective study.

Bozec A, Poissonnet G, Chamorey E, Casanova C, Vallicioni J, Demard F, Mahdyoun P, Peyrade F, Follana P, Bensadoun RJ, Benezery K, Thariat J, Marcy PY, Sudaka A, Dassonville O.

Laryngoscope. 2008 May;118(5):874-80. doi: 10.1097/MLG.0b013e3181644abd.

PMID:
18300703
14.

Comparison of quality of life in advanced laryngeal cancer patients after concurrent chemoradiotherapy vs total laryngectomy.

Trivedi NP, Swaminathan DK, Thankappan K, Chatni S, Kuriakose MA, Iyer S.

Otolaryngol Head Neck Surg. 2008 Nov;139(5):702-7. doi: 10.1016/j.otohns.2008.06.002.

PMID:
18984267
15.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

16.

Gender differences in pretreatment quality of life in a prospective lung cancer trial.

Siddiqui F, Kohl R, Swann S, Watkins-Bruner D, Movsas B.

J Support Oncol. 2008 Jan;6(1):33-9.

PMID:
18257399
17.

The Queensland Cancer Risk Study: general population norms for the Functional Assessment of Cancer Therapy-General (FACT-G).

Janda M, DiSipio T, Hurst C, Cella D, Newman B.

Psychooncology. 2009 Jun;18(6):606-14. doi: 10.1002/pon.1428.

PMID:
18942661
18.

Evaluating clinically meaningful change on the ITP-PAQ: preliminary estimates of minimal important differences.

Mathias SD, Gao SK, Rutstein M, Snyder CF, Wu AW, Cella D.

Curr Med Res Opin. 2009 Feb;25(2):375-83. doi: 10.1185/03007990802634119 .

PMID:
19192982
19.

Evaluating minimal important differences for the FACT-Melanoma quality of life questionnaire.

Askew RL, Xing Y, Palmer JL, Cella D, Moye LA, Cormier JN.

Value Health. 2009 Nov-Dec;12(8):1144-50. doi: 10.1111/j.1524-4733.2009.00570.x. Epub 2009 Jun 25.

PMID:
19558579
20.

Utility assessment in patients with mental disorders: validity and discriminative ability of the time trade-off method.

König HH, Günther OH, Angermeyer MC, Roick C.

Pharmacoeconomics. 2009;27(5):405-19. doi: 10.2165/00019053-200927050-00005.

PMID:
19586078
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk